Vittorio Pengo

Q: What Schools Are Affiliated With Vittorio Pengo

Vittorio Pengo is affiliated with the following schools: University of Milan, Stanford University, University of Padua

Vittorio Pengo's AcademicInfluence.com Rankings

Vittorio Pengo

Computer Science

#7606

World Rank

#8007

Historical Rank

Computational Linguistics

#1545

World Rank

#1562

Historical Rank

Machine Learning

#2859

World Rank

#2894

Historical Rank

Artificial Intelligence

#3152

World Rank

#3198

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Vittorio Pengo's Degrees

PhD Computer Science University of Milan
Bachelors Computer Science University of Milan

Similar Degrees You Can Earn

Why Is Vittorio Pengo Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Vittorio Pengo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. (2004) (1730)
Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) (1996) (1432)
Update of the guidelines for lupus anticoagulant detection (2009) (1111)
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. (2007) (758)
D-dimer testing to determine the duration of anticoagulation therapy. (2006) (527)
Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome (2010) (512)
EULAR recommendations for the management of antiphospholipid syndrome in adults (2019) (511)
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. (2018) (491)
The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. (1986) (465)
Chronic thromboembolic pulmonary hypertension. (2006) (455)
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. (2011) (390)
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans (2006) (386)
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance (2002) (371)
PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. (1992) (356)
Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. (2010) (319)
Antibody profiles for the diagnosis of antiphospholipid syndrome (2005) (305)
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial (2008) (289)
The association between circulating antibodies against domain I of beta2‐glycoprotein I and thrombosis: an international multicenter study (2009) (268)
A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy (2000) (244)
The Risk for Fatal Pulmonary Embolism after Discontinuing Anticoagulant Therapy for Venous Thromboembolism (2007) (222)
Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. (2011) (189)
Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis (2006) (182)
Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM) (2007) (178)
Autoantibodies to Phospholipid-binding Plasma Proteins in Patients with Thrombosis and Phospholipid-reactive Antibodies (1996) (171)
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). (2011) (170)
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. (2014) (169)
Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity (2006) (165)
Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. (2000) (162)
Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. (2014) (161)
Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH (2018) (160)
Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Risk of Bleeding (2001) (160)
Standardized Low–Molecular-Weight Heparin Bridging Regimen in Outpatients on Oral Anticoagulants Undergoing Invasive Procedure or Surgery: An Inception Cohort Management Study (2009) (157)
Autoimmune Antiphospholipid Antibodies Are Directed against a Cryptic Epitope Expressed when β2-Glycoprotein I Is Bound to a Suitable Surface (1995) (154)
A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy (2007) (149)
Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF (2016) (149)
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. (2010) (147)
Thrombotic Events during Oral Anticoagulant Treatment: Results of the Inception-cohort, Prospective, Collaborative ISCOAT Study (1997) (138)
Worldwide Management of Oral Anticoagulant Therapy: the ISAM Study (2006) (132)
Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. (2016) (131)
Immunological specificity and mechanism of action of IgG lupus anticoagulants. (1987) (128)
Influence of different IgG anticardiolipin antibody cut‐off values on antiphospholipid syndrome classification (2008) (123)
Features associated with epilepsy in the antiphospholipid syndrome. (2004) (121)
Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). (2001) (118)
Antiphospholipid syndrome: antibodies to Domain 1 of β2‐glycoprotein 1 correctly classify patients at risk (2015) (116)
Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. (1998) (116)
Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment (2011) (112)
Risks factors for highly unstable response to oral anticoagulation: a case‐control study (2005) (112)
Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples (2007) (110)
Immunological specificity and mechanism of action of IgG lupus anticoagulants (1987) (109)
Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) (109)
Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. (2015) (109)
Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome (2010) (107)
Low drug levels and thrombotic complications in high‐risk atrial fibrillation patients treated with direct oral anticoagulants (2018) (107)
Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. (2009) (104)
Risk stratification and outcomes in hemodynamically stable patients with acute pulmonary embolism: a prospective, multicentre, cohort study with three months of follow‐up (2009) (91)
Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile (2013) (88)
Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. (1993) (88)
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome (2017) (85)
dRVVT Is more Sensitive than KCT or TTI for Detecting Lupus Anticoagulant Activity of Anti-β2-glycoprotein I Autoantibodies (1999) (84)
The Redox Enzyme p66Shc Contributes to Diabetes and Ischemia-Induced Delay in Cutaneous Wound Healing (2010) (82)
Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. (2007) (78)
McMaster RARE‐Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome (2018) (78)
Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. (2003) (75)
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial (2016) (75)
Antibodies to Domain I of β(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). (2011) (75)
The Management of Oral Anticoagulant Therapy: The Patient’s Point of View (2000) (74)
Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper. (2014) (74)
Antiphospholipid syndrome and the heart: a case series and literature review. (2015) (71)
Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome. (1990) (71)
Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. (2007) (70)
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. (2015) (69)
Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study (2018) (65)
Detection of lupus anticoagulant in the era of direct oral anticoagulants. (2017) (65)
Prevalence and Clinical Correlations of Antibodies Against Six β2-Glycoprotein-I-Related Peptides in the Antiphospholipid Syndrome (2003) (64)
Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study (2016) (64)
VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. (2011) (64)
Correct laboratory approach to APS diagnosis and monitoring. (2013) (63)
Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta‐Analysis (2012) (62)
Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants (2019) (61)
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs (2018) (61)
What Have We Learned about Antiphospholipid Syndrome from Patients and Antiphospholipid Carrier Cohorts? (2012) (60)
IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. (1994) (59)
The left atrial appendage: from embryology to prevention of thromboembolism (2016) (58)
Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS) (2013) (58)
The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. (2019) (57)
Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2020) (56)
Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: a prospective multicenter study. (2000) (55)
The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. (2019) (52)
A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. (2007) (52)
A Comparison of a Moderate with Moderate-high Intensity Oral Anticoagulant Treatment in Patients with Mechanical Heart Valve Prostheses (1997) (51)
Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. (2009) (51)
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. (2010) (49)
The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation (2015) (49)
Long-term use of vitamin K antagonists and incidence of cancer: a population-based study. (2011) (47)
Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement (2008) (47)
Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation (2010) (47)
Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK). (2000) (45)
Simple and Safe Method to Prepare Patients With Prosthetic Heart Valves for Surgical Dental Procedures (2000) (43)
The Diagnosis of the Antiphospholipid Syndrome (2006) (43)
A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. (2013) (43)
Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases (2009) (42)
Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns. (2018) (42)
Prevalence of heart diseases in patients with pulmonary embolism with and without peripheral venous thrombosis: findings from a cross-sectional survey. (2009) (41)
Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles. (2015) (40)
Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome (2017) (40)
Tetra positive thrombotic antiphospholipid syndrome: Major contribution of anti‐phosphatidyl‐serine/prothrombin antibodies to lupus anticoagulant activity (2020) (39)
Antiphospholipid syndrome: critical analysis of the diagnostic path (2010) (39)
High blood ketone body concentration in Type 2 non-insulin dependent diabetic patients (1996) (39)
The long‐term risk of cancer in patients with a first episode of venous thromboembolism (2009) (38)
Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study (2009) (38)
A combination therapy to treat second-degree anti-Ro/La-related congenital heart block. A strategy to avoid stable third-degree heart block? (2012) (37)
Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti-Beta2-Glycoprotein I IgG ELISAs (2013) (36)
The role of platelets in antiphospholipid syndrome (2017) (36)
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study. (2018) (36)
ISTH guidelines on lupus anticoagulant testing. (2012) (35)
Sex, age and normal post‐anticoagulation D‐dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension (2010) (35)
High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. (2012) (35)
A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment. (2003) (34)
Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome (2013) (34)
Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature. (2009) (34)
The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository (2019) (34)
Thrombocytopenia in high‐risk patients with antiphospholipid syndrome (2018) (34)
Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution. (2019) (34)
Some Patients with Antiphospholipid Syndrome Express hitherto Undescribed Antibodies to Cardiolipin-binding Proteins (2001) (33)
Deep Venous Thrombosis After Surgery for Inflammatory Bowel Disease: Is Standard Dose Low Molecular Weight Heparin Prophylaxis Enough? (2010) (33)
Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago (2017) (33)
Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago (2017) (33)
Adenosine Diphosphate (ADP)-Induced ⍺-Granules Release from Platelets of Native Whole Blood Is Reduced by Ticlopidine but Not by Aspirin or Dipyridamole (1986) (32)
A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome (2008) (32)
Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective. (2018) (32)
Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry (2018) (32)
Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies (2019) (31)
Apolipoprotein E (APOE) and warfarin dosing in an Italian population (2005) (31)
Antiphospholipid antibodies are not present in the membrane of gel‐filtered platelets of patients with IgG anticardiolipin antibodies, lupus anticoagulant and thrombosis (1993) (31)
APS - Diagnostics and challenges for the future. (2016) (31)
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). (2010) (30)
Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome (2015) (30)
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results (2012) (30)
Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study (2020) (30)
Low-Intensity Oral Anticoagulant Plus Low-Dose Aspirin During the First Six Months Versus Standard-Intensity Oral Anticoagulant Therapy After Mechanical Heart Valve Replacement: A Pilot Study of Low-Intensity Warfarin and Aspirin in Cardiac Prostheses (LIWACAP) (2007) (29)
The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism (2018) (29)
Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome (2012) (29)
The risk of cancer in patients with venous thromboembolism does not exceed that expected in the general population after the first 6 months (2010) (29)
The challenges of lupus anticoagulants (2016) (28)
Antibodies to oxidized LDL/beta2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism. (2008) (28)
A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation (2015) (28)
Diagnosis and therapy of antiphospholipid syndrome. (2015) (27)
The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE (2016) (27)
15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report (2017) (27)
Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study (2018) (26)
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two‐year outcomes after the study closure (2020) (26)
Utilization of Dilute Russell’s Viper Venom Time to Detect Autoantibodies against β2-Glycoprotein I which Express Anticoagulant Activity in the Presence but not in the Absence of Exogenous Phospholipids (1997) (26)
Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension　- A Systematic Review and Meta-Analysis. (2019) (26)
Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment (2003) (26)
Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. (2013) (25)
Procoagulant effect of anti-beta2-glycoprotein I antibodies with lupus anticoagulant activity. (1999) (25)
APS--controversies in diagnosis and management, critical overview of current guidelines. (2011) (25)
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. (2021) (25)
Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non‐valvular atrial fibrillation (2016) (24)
Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation. (2017) (24)
More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required (2011) (24)
Laboratory Diagnostics of Antiphospholipid Syndrome (2017) (24)
Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry (2018) (23)
β2‐Glycoprotein I binds to thrombin and selectively inhibits the enzyme procoagulant functions (2013) (23)
Thrombophilia in young patients with cryptogenic stroke and patent foramen ovale (PFO) (2007) (23)
Antiphospholipid Syndrome in Chronic Thromboembolic Pulmonary Hypertension: A Well-Defined Subgroup of Patients (2019) (23)
Chemical synthesis and characterization of wild‐type and biotinylated N‐terminal domain 1–64 of β2‐glycoprotein I (2010) (22)
Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis (2019) (22)
Laboratory testing for antiphospholipid syndrome (2016) (22)
Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report. (2018) (22)
The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures (2018) (22)
Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome (2017) (21)
Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study. (2017) (21)
Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants (2015) (21)
Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. (2020) (21)
Purification of anticardiolipin and lupus anticoagulant activities by using cardiolipin immobilized on agarose beads. (1993) (21)
Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant (2017) (21)
An Approach to Differential Diagnosis of Antiphospholipid Antibody Syndrome and Related Conditions (2014) (20)
A guide to oral anticoagulant therapy (1998) (19)
Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study (2013) (19)
Clinical management of rivaroxaban-treated patients (2013) (19)
Argatroban in the management of heparin-induced thrombocytopenia (2010) (18)
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single‐Patient Data Meta‐Analysis in More Than 15,000 Individuals (2019) (18)
Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis. (2017) (18)
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). (2019) (18)
Antithrombin III Padua: a "new" congenital antithrombin III abnormality with normal or near normal activity, normal antigen, abnormal migration and no thrombotic disease. (1983) (17)
A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty (2011) (17)
Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry (2020) (17)
Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome (2020) (17)
Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite Antiphospholipid Syndrome (2012) (17)
Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study (2005) (17)
Knowledges about herbal products among subjects on warfarin therapy and patient–physician relationship: a pilot study (2007) (17)
To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort (2015) (17)
Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry (2018) (17)
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry (2020) (16)
Duration of anticoagulation after isolated pulmonary embolism (2016) (16)
Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis. (2019) (16)
Antiphospholipid syndrome: interpretation of laboratory data (2011) (16)
Anti-β2-glycoprotein I ELISA assay: The influence of different antigen preparations (2009) (16)
A guide to oral anticoagulant treatment. Recommendations of the Italian federation of anticoagulation clinics (FCSA) (2003) (16)
Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review (2017) (16)
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study (2010) (16)
Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms (2016) (15)
International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain (2018) (15)
The Risk of Overdiagnosis of Antiphospholipid Antibody Syndrome (2001) (15)
Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients. A retrospective propensity score matched cohort study. (2018) (15)
Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's. (2017) (14)
The J-elongated conformation of β2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome (2020) (14)
Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel. (2017) (14)
A guide to oral anticoagulant treatment (1998) (14)
The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. (2019) (14)
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry (2019) (14)
Molecular mapping of α-thrombin (αT)/β2-glycoprotein I (β2GpI) interaction reveals how β2GpI affects αT functions. (2016) (13)
Risk-based secondary prevention of obstetric antiphospholipid syndrome (2012) (13)
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention (2009) (13)
Biological variation of INR in stable patients on long-term anticoagulation with warfarin. (2012) (13)
Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome (2006) (13)
Diabetic ketosis activates lymphomonocyte‐inducible nitric oxide synthase (2002) (13)
Comparison between routine laboratory prothrombin time measurements and fingerstick determinations using a near-patient testing device (Pro-Time). (2000) (12)
An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an International Normalised Ratio above 10.0 (2009) (12)
DOAC plasma levels measured by chromogenic anti‐Xa assays and HPLC‐UV in apixaban‐ and rivaroxaban‐treated patients from the START‐Register (2020) (12)
Emerging anticoagulants (2011) (12)
Real-world persistence with direct oral anticoagulants (DOACs) in naïve patients with non-valvular atrial fibrillation. (2019) (12)
Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry (2019) (12)
[Hemorrhagic complications of oral anticoagulant therapy: results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy)]. (1997) (12)
Bileaflet mechanical heart valve closing sounds: in vitro classification by phonocardiographic analysis (2009) (11)
Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review. (2020) (11)
Secondary prevention in thrombotic antiphospholipid syndrome (2012) (11)
Laboratory tests during direct oral anticoagulant treatment? Yes (2013) (11)
Binding of autoimmune cardiolipin-reactive antibodies to heparin: a mechanism of thrombosis? (1995) (11)
Clinical value of anti-domain I-β2Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study. (2018) (11)
Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). (2018) (11)
Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START‐Laboratory Register (2018) (11)
From acute pulmonary embolism to chronic thromboembolic pulmonary hypertension. (2005) (11)
Family history of venous thrombosis or sudden death as a risk factor for venous thromboembolism (2012) (11)
Management of patients on long-term oral anticoagulant therapy undergoing elective surgery: survey of the clinical practice in the Italian anticoagulation clinics (2007) (11)
Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes (2017) (10)
Laboratory criteria for antiphospholipid syndrome: reply (2018) (10)
Reduction of annexin A5 anticoagulant ratio identifies antiphospholipid antibody‐positive patients with adverse clinical outcomes (2017) (10)
Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation (2015) (10)
The Paradox of the Lupus Anticoagulant: History and Perspectives (2014) (10)
Cancer prevention and vitamin K antagonists: an overview. (2010) (10)
Insight into the hypercoagulable state of high‐risk thrombotic APS patients: Contribution of aβ2GPI and aPS/PT antibodies (2020) (10)
Optimizing quality care for the oral vitamin K antagonists (VKAs). (2018) (9)
Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study (2012) (9)
The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs (2013) (9)
Interpretation of laboratory data and need for reference laboratories (2012) (9)
Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. (2011) (9)
Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). (2018) (9)
Four good reasons to appreciate triple positivity. (2016) (9)
The negative predictive value of D‐dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: A prospective cohort study (the PROLONG PLUS study) (2012) (9)
In-vitro detection of thrombotic formation on bileaflet mechanical heart valves. (2011) (9)
Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository (2020) (9)
Application of Wavelet Analysis to the Phonocardiographic Signal of Mechanical Heart Valve Closing Sounds (2009) (9)
Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome (2021) (8)
Serum of normal subjects contains IgG with antibody-like specificity for phospholipids. (1984) (8)
Consequences of warfarin suspension after major bleeding in very elderly patients with non valvular atrial fibrillation (2017) (8)
Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register (2020) (8)
Lupus Anticoagulant Testing: Diluted Russell Viper Venom Time (dRVVT). (2017) (8)
Immunosuppressive treatment in a heart transplantation candidate with antiphospholipid syndrome (1996) (8)
Clinical Relevance of β2-Glycoprotein-I Plasma Levels in Antiphospholipid Syndrome (APS) (2014) (8)
Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity? (2021) (8)
Standardization of lupus anticoagulant. Feasibility study of a calibration model to minimize between-method variability. (2011) (8)
Initiation of Warfarin Treatment in Outpatients with Nonrheumatic Atrial Fibrillation: A Scheme for Early Indication of Maintenance Dose (1998) (8)
Sex and anticoagulation in patients with idiopathic venous thromboembolism (2006) (8)
Impact of COVID-19 and COVID-19 vaccination on high-risk patients with Antiphospholipid Syndrome: a nationwide survey (2022) (8)
Contemporary Burden of Atrial Fibrillation and Associated Mortality in Northeastern Italy. (2016) (7)
Investigational anticoagulants for hematological conditions: a new generation of therapies (2013) (7)
Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository (2019) (7)
The optimal therapeutic range for oral anticoagulant treatment as suggested by fibrinopeptide A (FpA) levels in patients with heart valve prostheses (1989) (7)
D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the prolong extension study (2007) (7)
[Anti-beta2 glycoprotein I-beta2 glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases. (1999) (7)
Oral and Poster Presentations (2003) (7)
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study (2019) (7)
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study (2019) (7)
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: From the START antiplatelet registry. (2020) (7)
In vitro characterization of bileaflet Mechanical Heart Valves closing sound (2008) (7)
Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy. (2015) (7)
Comparative classification of thrombotic formations on bileaflet mechanical heart valves by phonographic analysis (2011) (7)
False‐negative or false‐positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant: a rebuttal (2011) (7)
Management of oral anticoagulant treatment in patients with venous thromboembolism. (2006) (7)
Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology (2020) (6)
Laboratory diagnosis of antiphospholipid syndrome. (2011) (6)
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. (2020) (6)
Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome: Response from Pengo (2020) (6)
Beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) release by adenosine diphosphate (ADP) contact with native whole blood. (1985) (6)
Can we use NOACS in APS? (2019) (6)
Oral anticoagulant treatment in very elderly patients with atrial fibrillation (2001) (6)
Current anticoagulant safety (2012) (6)
Dosing of clopidogrel and aspirin in acute coronary syndromes. (2010) (6)
Prevalence of aPhosphatidylserine/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: A systematic review and meta-analysis. (2022) (5)
[Antithrombotic treatments in patients with SARS-CoV-2 infection: from current evidence to reasonable recommendations - A position paper from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology]. (2020) (5)
Mortality associated to atrial fibrillation still on the rise: United States, 1999 to 2014. (2016) (5)
Antibody profiles comprising anti phosphatidylserine/prothrombin differently affect thrombin generation and protein C resistance in antiphospholipid antibody carriers. (2020) (5)
Prothrombin Is Responsible for the Lupus Cofactor Phenomenon in a Patient with Lupus Anticoagulant/Hypoprothrombinemia Syndrome (2020) (5)
Low Molecular Weight Heparin during Surgery in Parients on Long Term Oral Anticoagulant Treatment (OAT): A Prospective Observational Study. (2004) (5)
Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository (2022) (5)
Enhanced “In Vitro“ Release of Platelet α-Granules After Acute Myocardial Infarction (AMI) (1985) (5)
Self-testing and self-monitoring of oral anticoagulant therapy: consensus of the Italian Federation of Anticoagulation Clinics (2003) (5)
760 Prevalence of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the start-antiplatelet registry (2021) (5)
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry (2022) (4)
Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes (2021) (4)
Monitoring oral anticoagulants: new strategies for an emerging problem (2006) (4)
General population screening for atrial fibrillation with an automated rhythm-detection blood pressure device. (2020) (4)
Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry (2019) (4)
Comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic diseases in patients with and without malignancy (2000) (4)
An in vitro model to mimic the thrombotic occlusion of small vessels in catastrophic antiphospholipid syndrome (CAPS) (2019) (4)
Effect of Anti-β2Glycoprotein I Lupus Anticoagulants on Fibrin Polymerization and Fibrinolysis (2000) (4)
Ultrasound phonocardiography for detecting thrombotic formations on bileaflet mechanical heart valves. (2013) (4)
Radioiodinated fibrinogen in the evaluation of patients with osteosarcoma. (1980) (4)
New trends in anticoagulant therapy. (2004) (4)
Risk of reoperation in bioprosthetic valve patients with indication for long-term anticoagulation. Results from the observational retrospective multicentre PLECTRUM study (2018) (4)
[A Censis survey on atrial fibrillation awareness in the general population and among general practitioners and affected patients in Italy]. (2014) (4)
Critical Update of the Antiphospholipid Syndrome Criteria (2010) (4)
Death rates and causes in anticoagulated atrial fibrillation patients: a population-based study. (2020) (4)
Antiphospholipid syndrome classification criteria: comments on the letter of Swadzba and Musial (2009) (4)
Critical Update of the Antiphospholipid Syndrome Criteria~!2009-10-17~!2009-10-20~!2010-03-11~! (2010) (4)
Preliminary hemocompatibility assessment of an innovative material for blood contacting surfaces (2021) (4)
Accelerated Atherosclerosis in the Aortic Arch and Cerebral Ischemia in a Patient with Primary Antiphospholipid Syndrome (2001) (4)
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (‘Registry’) (2022) (4)
Oral anticoagulant therapy in patients with atrial fibrillation. (2003) (4)
Interventional approach to reduce thromboembolic risk in patients with atrial fibrillation ineligible for oral anticoagulation. (2005) (4)
Oral Anticoagulation Treatment in the Elderly (2016) (3)
Is the analysis over the time domain or over the frequency domain significant for the detection of bileaflet mechanical heart valve dysfunction? (2009) (3)
Monitoring liver regeneration after right hepatectomy. (1985) (3)
The D-dimer (DD) test to establish the duration of anticoagulation after a first unprovoked episod of venous thromboembolism (VTE); the prospective randomized “Prolong” Study on behalf of the Italian Federation of Anticoagulation Clinics (FCSA) (2005) (3)
Direct Oral Anticoagulants vs Vitamin-K Antagonists in Thrombotic Antiphospholipid Syndrome: Meta-analysis of Randomized Controlled Trials. (2022) (3)
A Novel ELISA Assay for the Detection of Anti-Prothrombin Antibodies in Antiphospholipid Syndrome Patients at High Risk of Thrombosis (2021) (3)
Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism (2020) (3)
Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial (2018) (3)
Lupus Anticoagulant Testing (2007) (3)
Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study (2011) (3)
Right ventricular dysfunction in patients diagnosed with pulmonary embolism (2010) (3)
Anti β2-glycoprotein I antibodies in a patient with catastrophic antiphospholipid syndrome (1995) (3)
Higher levels of plasma matrix metalloproteinase-2 are associated with a significantly increased risk of arterial thrombosis in patients with the antiphospholipid syndrome. (2012) (3)
Long‐term warfarin use to prevent both stroke and dementia in subjects with atrial fibrillation? (2004) (3)
Autoimmune antiphospholipid antibodies: what is their true target? (1995) (3)
Antibodies to Domain 1 ( Dm 1 ) of β 2-Glycoprotein 1 ( β 2 GP 1 ) correctly classify patients at risk in Antiphospholipid Syndrome ( APS ) (2015) (3)
Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma: comment (2016) (3)
A Bridging Protocol in High-Thrombotic Risk Mechanical Valve Bearers Undergoing Surgery or Invasive Procedures. (2016) (2)
Mechanical Prosthetic Heart Valve Thrombosis Despite Optimal Anticoagulation in a Patient with Congenital Thrombophilia (Factor V Leiden) (2003) (2)
[Abnormal fibrin polymerization and its clinical usefulness in patients with chronic liver disease (author's transl)]. (1981) (2)
Development of Artificial Neural Network–Based Algorithms for the Classification of Bileaflet Mechanical Heart Valve Sounds (2012) (2)
Anti‐β2‐glycoprotein I antibody testing in the laboratory diagnosis of antiphospholipid syndrome (2005) (2)
Fatal Cerebral Hemorrhage Complicating Thromboembolic Stroke in a Patient with Prosthetic Mitral Valve Thrombosis Treated with Thrombolytic Therapy (1997) (2)
Mild inflammation may switch on again atrial fibrillation after successful electrical cardioversion (2009) (2)
MiRNA 126 as a New Predictor Biomarker in Venous Thromboembolism of Persistent Residual Vein Obstruction: A Review of the Literature Plus a Pilot Study (2021) (2)
Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials (2020) (2)
Do malfunctioning bioprosthetic heart valves represent a potential thrombogenic focus? (1985) (2)
Fibrinogen degradation products (F.D.P.) in ascitic fluid of patients affected by ovarian cancer. (1981) (2)
Platelet- and endothelial-derived microparticles in the context of different antiphospholipid antibody profiles (2022) (2)
Behavior of Antithrombin III, Determined as Protein Concentration and Biologic Activity, in Subjects with Neoplastic Disease (1982) (2)
New trends in anticoagulant treatments (2005) (2)
A brief contact of native whole blood with adenosine diphosphate (ADP) promotes the release of the contents of platelet alpha granules but not dense bodies and increases platelet retention to glass bead columns. (1990) (2)
Low intensity warfarin therapy. (1997) (2)
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal (2013) (2)
Diagnosis and therapy of antiphospholipid syndrome. Author's reply. (2015) (2)
Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register (2021) (2)
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study (2022) (2)
Interaction between Antiphospholipid Antibodies and Protein C Anticoagulant Pathway: A Narrative Review (2022) (2)
Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case‐control study (2018) (2)
Positive stress test in a patient with patent coronary artery grafts (2006) (1)
Abstracts of the 25th Biennial International Congress on Thrombosis (2018) (1)
Association of Antiplatelet and Anticoagulant Treatment in Patients with Mechanical Prosthetic Heart Valves. Data from the Observational Multicentre PLECTRUM Study (2021) (1)
The importance of simple coagulation tests (fibrinogen assays and thrombin coagulase clotting time) in the diagnosis of liver cancer. (2014) (1)
Fibrinogen degradation products (F.D.P.) in ascitic fluid of patients affected by ovarian cancer. (1981) (1)
Prescription of vitamin K inhibitors in low-risk patients with atrial fibrillation (2011) (1)
[Organizational model for dental treatment of patients on antithrombotic prophylaxis with oral anticoagulants]. (1989) (1)
Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti-β 2 -Glycoprotein I IgG Elisas Influences the Diagnosis of the Antiphospholipid Syndrome (2012) (1)
Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome (2012) (1)
PBR6 ISAM: INTERNATIONAL STUDY OF ANTICOAGULATION MANAGEMENT.THE ITALIAN EXPERIENCE (2004) (1)
Effect of body mass index on ischemic and bleeding events in patients presenting with acute coronary syndromes: insights from the START-ANTIPLATELET registry (2020) (1)
Prasugrel for the treatment of patients with acute coronary syndrome (2009) (1)
[Prevention of deep venous thrombosis with low-dose heparin in patients with acute uncomplicated myocardial infarct: double-blind controlled study]. (1986) (1)
Fluctuation of Anti-Domain 1 and Anti-Β2 Glycoprotein I Antibody Titers Over Time in Patients with Persistently Positive Antiphospholipid Antibodies. (2023) (1)
Crystal structure of Beta-2 glycoprotein I purified from plasma (pB2GPI) (2020) (1)
Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository (2021) (1)
Antiphospholipid Syndrome in Patients with Venous Thromboembolism. (2022) (1)
Warfarin prescription in patients with nonvalvular atrial fibrillation and one non–gender‐related risk factor (CHA2DS2VASc 1 or 2): A treatment dilemma (2018) (1)
Data from a multidisciplinary poll of 178 expert physicians on the usage of non-vitamin K Oral Anticoagulants in patients with atrial fibrillation and venous thromboembolism (2017) (1)
A GENERAL MECHANISM FOR LUPUS ANTICOAGULANTS (1987) (1)
Oral anticoagulants in thrombotic antiphospholipid syndrome: Leave the old road for a new trail? (2020) (1)
CYP2C9 polymorphism and warfarin dose requirement (2000) (1)
Phonocardiographic Classification of Mechanical Heart Valves Using Artificial Neural Networks (2009) (1)
[Study of blood platelet activation in migraine in childhood]. (1987) (1)
Antiphospholipid syndrome: Reversal of antiphosphatidylserine/prothrombin-induced activated protein C resistance. (2022) (1)
[Home use of an ambulatory monitor for the determination of prothrombin time (coaguchek) in patients treated with oral anticoagulants. Multicenter prospective study]. (1999) (1)
The use of laser-nephelometry in evaluating fibrinogenaemia in patients with hepatocarcinoma and cirrhosis. (1985) (1)
Standardization of lupus anticoagulant. The Lupus Anticoagulant Sensitivity Index (LASI) (2012) (1)
Mitral valve endocarditis due to Staphylococcus capitis in a very old woman (2014) (1)
Special issue: Late consequences of venous thromboembolism. (2018) (1)
Thrombophilia testing in the real-world clinical setting of thrombosis centres taking part in the Italian Start 2-Register. (2021) (1)
Management of special conditions in patients on vitamin K antagonists (2012) (1)
Gender Related Differences in Gastrointestinal Bleeding With Oral Anticoagulation in Atrial Fibrillation (2022) (1)
Anticoagulant Selection in Relation to SAMe-TT2R2 Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry. (2020) (1)
Therapeutic value and innovation of a drug and criteria for evaluation: A multidisciplinary experience in the Veneto Region (2015) (1)
Antiphosphlipid syndrome classification criteria: comments to the Letter of Jakub Swadzba and Jacek Musial. (2009) (1)
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository Analysis: The Comparison of Real World and Core Laboratory Antiphospholipid Antibody ELISA Results (2016) (1)
Residual venous obstruction and D-dimer as risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis in the prolong study (2008) (1)
Classification of patients with antiphospholipid syndrome into risk categories: An evolving process (2006) (1)
THU0561 Clinical practice guideline for diagnosis and management of catastrophic antiphospholipid syndrome (2017) (1)
Antiphospholipid antibodies in chronic thromboembolic pulmonary hypertension. (2023) (1)
Review 1: "A Prothrombotic Thrombocytopenic Disorder Resembling Heparin-Induced Thrombocytopenia Following Coronavirus-19 Vaccination" (2021) (0)
[Thromboembolism in non-rheumatic atrial fibrillation]. (2001) (0)
[Clinical importance of the determination of antithrombin III by the use of a chromogenic substrate, in cases of disseminated intravascular coagulation and of acute hepatic insufficiency]. (1981) (0)
[Effect of the degree of anticoagulation on the plasma levels of beta-thromboglobulin in patients with heart valve prostheses treated with warfarin]. (1984) (0)
Immunological Specificity and Mechanism of Action of (2017) (0)
Mo-P1:127 Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis (2006) (0)
Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An APS ACTION Study. (2023) (0)
population-based study Long-term use of vitamin K antagonists and incidence of cancer: a (2011) (0)
LUPUS ANTICOAGULANT : SENSIBILITA E SPECIFICITA DEI TEST DI COMUNE IMPIEGO (1998) (0)
VKORC1, CYP2C9 AND CYP4F2 GENETIC BASED ALGORITHM FOR WARFARIN DOSING. PRELIMINARY RESULTS OF A PROSPECTIVE ITALIAN STUDY (2011) (0)
Solid phase immunoaffinity purification of anticardiolipin antibodies (1991) (0)
[Concepts and preconceptions on the use of direct oral anticoagulants in Italy: a Delphi consensus panel of the Atherosclerosis Thrombosis, Vascular Biology Study Group (ATBV)]. (2021) (0)
Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial (2018) (0)
Kronik tromboembolik pulmoner hipertansiyon Chronic thromboembolic pulmonary hypertension (2014) (0)
BETA-THR~I0BULIN ('s -'IIS) AND PIA'TELET FAcMlR 4 (PF4) RELEASE BY ADENOSINE DIPHOSPHATE (ADP) CONTACTWITHNATIVEWHOLE = (1985) (0)
A pharmacokinetic-pharmacodynamic method for predicting warfarin maintenance dose. Preliminary results (2003) (0)
Laboratory diagnosis of antiphospholipid syndrome La diagnosi di laboratorio della sindrome da antifosfolipidi (2007) (0)
Changes in alpha 1-antitrypsin (AAT) and alpha 2-macroglobulin serum concentrations during treatment with oral estro-progestogens. (1982) (0)
4110Thromboembolic and bleeding risk of patients with left-sided mechanical heart prostheses: the FCSA-START-Valvole Study (2017) (0)
The Three Players of Mechanical Valve Thrombosis: Cancer, Anticancer Therapy, and Thromboprophylaxis. (2016) (0)
Crystal structure of human recombinant Beta-2 glycoprotein I (hrB2GPI) (2020) (0)
Effect of patient's sex on risk of recurrent venous thromboembolism : a meta-analysis. Commentary (2007) (0)
Laboratory diagnosis of antiphospholipid syndrome La diagnosi di laboratorio della sindrome da antifosfolipidi (2007) (0)
In vitro investigations on prosthetic valve thrombosis by ultrasound phonocardiography (2013) (0)
NOW: /A Proe pective g Multicenter, Randomized, C Cfinical Investigation of the Effects of Sulodexide in Preventi five Cardiovascular Accidents W the Ffirst Year After Acute Myocardial Infarction (2016) (0)
Role of antiplatelet agents and anticoagulants in a neurological population (2008) (0)
Blood pressure (BP) control in patients with atrial fibrillation (AF). A 24-h ambulatory blood pressure monitoring (ABPM) study, before and after electric cardioversion (ECV) (2013) (0)
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Procoagulant Effect of Anti-b2-Glycoprotein I Antibodies With Lupus Anticoagulant Activity (2016) (0)
Ischemic and bleeding risk stratification in diabetic patients after acute coronary syndrome based on insulin requirement (2020) (0)
VKORC1 AND CYP2C9 pharmacogenetics: relevance in warfarin maintenance dosing prediction. (2009) (0)
Renal arterythrombosis andhypertension ina 13yearoldgirl withantiphospholipid syndrome (1990) (0)
Long-term use of vitamin K antagonists in patients with atrial fibrillation and cancer incidence: a pharmaco-epidemiological study (2013) (0)
Phonographic Analysis for Detecting Thrombotic Formations in MHVs Recipients (2011) (0)
An unusual acute coronary syndrome: undisclosed disease hidden under a confounding clinical presentation (2012) (0)
Discussion: Contemporary guidelines on implantable cardioverter defibrillator (ICD) therapy do not specifically address recommendations for secondary prevention after life-threatening ventricular arrhythmias due to vasospasm. The arrhythmic risk of coronary vasospasm (2020) (0)
A pharmacokinetic-pharmacodynamic model for individualisation of an oral anticoagulation therapy (2016) (0)
Prévention primaire de la thrombose par aspirine chez les patients porteurs d’anticorps antiphospholipides : analyse poolée des données individuelles de 5 cohortes internationales (2013) (0)
Thrombosis and hemostasis at the University of Padua: a reappraisal on the occasion of its 800th year of history (2022) (0)
Association between Severe Acute Respiratory Syndrome Coronavirus 2Infection (Coronavirus Disease 2019) and Lupus Anticoagulant-Hypoprothrombinemia Syndrome: A Case Report and Literature Assessment (2023) (0)
Vitamin K to correct overanticoagulation. (2009) (0)
[Neurologic complications of acute viral hepatitis. Electroencephalographic and biohumoral aspects]. (1982) (0)
Oral Anticoagulants in Low Risk Atrial Fibrillation Patients: A Population Based Study (2020) (0)
Optimizing Quality Care for the Oral VKAs (2018) (0)
[Advantages of a cardiologic ambulatory care facility specifically organized for patients undergoing treatment with oral anticoagulant drugs]. (1989) (0)
Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants (2015) (0)
[IgG anti-beta 2-glycoprotein I beta 2-glycoprotein I] immune complexes in patients with antiphospholipid (aPL) syndrome (1998) (0)
458Real world persistence with direct oral anticoagulants in anticoagulation naive patients with atrial fibrillation (2019) (0)
Variability in exposure of epitope G40-R43 of domain in manual and automated commercial anti-beta2-glycopreotein I IgG immunoassays (2015) (0)
COVID-19 pandemic affects the ability of negative D-dimer to identify venous thromboembolism patients at low risk of recurrence: insights from the Apidulcis study (2022) (0)
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome (2016) (0)
P6515Balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis (2019) (0)
OC-15 - Risk factors for cancer development after idiopathic venous thromboembolism. (2016) (0)
Role of cardiac magnetic resonance in patients with chest pain and pulmonary aneurysm (2011) (0)
Ultrasound Phonocardiography for the Functional Assessment of Mechanical Heart Valves (2011) (0)
Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry (2022) (0)
[Comparability of efficacy and safety results among phase III trials of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation]. (2017) (0)
THROMBIN FORMATION ACROSS CAROTID-ARTERY ATHEROSCLEROTIC PLAQUES (1993) (0)
Antithrombotic strategies for atrial fibrillation: on the threshold of changes? No (2005) (0)
Incidence of atrial fibrillation in an opportunistic screening campaign in a general practitioner setting: a prospective population study (2020) (0)
Clinical and Laboratory Characteristics of Persistently Antiphospholipid Antibody Positive Patients: Retrospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (""Registry"") (2018) (0)
Which treatments should be administered to patients with advanced dementia? Differential effects of life expectancy on the opinions of Italian physicians and nurses (2013) (0)
The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients (2019) (0)
The Paradox of Lupus Anticoagulant (2015) (0)
Effect of a computer-aided management of treatment quality of anticoagulated patients: a prospective randomized multicenter trial. APROAT (Automated Program for Oral Anticoagulant Treatment) (2001) (0)
LOW-INTENSITY (INR TARGET 1,8) VERSUS STANDARD ANTICOAGULATION FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION: A RANDOMIZED SINGLE CENTRE STUDY IN ELDERLY PATIENTS (2007) (0)
Role of anticoagulants in a neurological population: primary and secondary prevention of cardioembolic stroke (2008) (0)
A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation (2022) (0)
Venous tromboembolism treatment: budget impact analysis of rivaroxaban in Italy (2014) (0)
Should patients with mitral stenosis and atrial fibrillation receive combined antithrombotic therapy? (2006) (0)
Effect of anti beta2-glycoprotein I Lupus Anticoagulant antibodies on clotting time in the presence of human umbilical vein endothelial cells (2004) (0)
Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results (2022) (0)
X-ray and solution structures of human beta-2 glycoprotein I reveal a new mechanism of autoantibody recognition (2020) (0)
Dyspnoea in a young woman: the opposite of every truth is just as true (2016) (0)
[Degradation products of fibrinogen in synovial fluid]. (1979) (0)
A standardized bridging regimen for the peri-procedural management of high risk patients with mechanical heart valves (2010) (0)
D-dimer trends elaborate the heterogeneity of risk in hospitalized patients with COVID-19: A multi-national case series from different waves (2023) (0)
P4671A well-defined subgroup of chronic thromboembolic pulmonary hypertension patients are positive for antiphospholipid antibodies (2019) (0)
Anti beta 2-glycoprotein I antibodies in a patient with catastrophic antiphospholipid syndrome. (1995) (0)
Advances in Basic, Laboratory and Clinical Aspects of Thromboembolic Diseases* LOW INTENSITY WARFARIN THERAPY (1997) (0)
Identification of Methionine Sulfoxide at Position 1606 of von Willebrand Factor as a Risk Factor for Thrombosis in Patients with Antiphospholipid Syndrome (2016) (0)
[Thrombolytic therapy with urokinase in 8 patients with massive pulmonary thromboembolism]. (1985) (0)
Neural Networks: a novel method for early detection of mechanical heart valve thrombosis (2010) (0)
[Primary pulmonary hypertension and anticoagulant therapy]. (1996) (0)
P064 STANDARD DOSE LOW MOLECULAR WEIGHT HEPARIN PROPHYLAXIS FOR DEEP VENOUS THROMBOSIS AFTER SURGERY FOR INFLAMMATORY BOWEL DISEASE (2007) (0)
Crystal structure of human recombinant Beta-2 glycoprotein I short tag (ST-B2GPI) (2020) (0)
[Current management of oral anticoagulant treatment]. (2002) (0)
Commentary (1953) (0)
DETECTION OF ANTI-BETA2-GLYCOPROTEIN I ANTIBODIES: THE INFLUENCE OF DIFFERENT ANTIGEN PREPARATIONS (2007) (0)
Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes (2017) (0)
In vitro classification of thrombotic deposits on a bileaflet mechanical heart valve by artificial neural network (2010) (0)
Correlations between the enantio- and regio-selective metabolisms of warfarin. (2017) (0)
PO-33 D-dimer testing to determine duration of anticoagulation and risk of occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study (2010) (0)
Bidimensional Immunoelectrophoresis Abnormal Migration of Serum Antithrombin III in Coumarin-Treated Patients (1981) (0)
Anti-NET antibodies in antiphospholipid antibody-positive patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository. (2023) (0)
[Coagulation disorders after placement of a peritoneojugular valve]. (1980) (0)
A Possible Role Of Factor VIII Coagulation And Cyclic Nucleotides In Promoting Endothelial Renal Injury (1981) (0)
Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) (2022) (0)
INVITED NARRATIVE REVIEW DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF DEEP VEIN THROMBOSIS: FROM THE MID ’80 TO THE PRESENT DAY (by Paolo Prandoni) Diagnosis of deep vein thrombosis (2022) (0)
Efficacy and safety of rt-PA (Alteplase®) plus heparin vs heparin alone in pulmonary embolism (PE): PAIMS-2 results (1992) (0)
Heart and APS (2015) (0)
[Prevention of thromboembolism in non-rheumatic atrial fibrillation: an update]. (2001) (0)
Duration of anticoagulation treatment after an acute episode of pulmonary embolism (1990) (0)
X-Ray Crystallographic and Single-Molecule Fluorescence Studies of Beta-2 Glycoprotein I Reveal an Alternative Mechanism of Autoantibody Recognition (2019) (0)
The Evaluation of Fibrinogen Behavior in Hodgkin's Disease: Correlation with Clinical Stage (1983) (0)
Acute abdomen in a woman with a Bjork-Shiley heart valve prosthesis (1990) (0)
"How we treat" clinical dilemmas in antiphospholipid syndrome: A case-based approach. (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Vittorio Pengo?

Vittorio Pengo is affiliated with the following schools:

Vittorio Pengo's Academic­Influence.com Rankings

Vittorio Pengo's Degrees

Similar Degrees You Can Earn

Why Is Vittorio Pengo Influential?

Vittorio Pengo's Published Works

Published Works

What Schools Are Affiliated With Vittorio Pengo?

Vittorio Pengo's AcademicInfluence.com Rankings